U.S. Cannabis Legislation: Key Updates & Business Insights
Stay updated on U.S. cannabis legislation in Florida, Nebraska, and North Dakota. Learn how these changes affect cannabis businesses and compliance.
One of the most significant aspects of the Cannabis Act and Regulations is the introduction of a Cannabis Drug License, which will help pave the way for companies looking to develop prescription cannabis-based medications.
This license gives companies the ability to produce and sell prescription drugs containing cannabis. Its inclusion in the Act could turn out to be especially beneficial for consumers, as while medical cannabis isn’t currently covered by insurance, the Act requires that cannabis medicines be given drug-identification numbers, which will provide them with coverage. The first step for companies with the goal of making advancements in cannabis-based drugs is obtaining this license. One important stipulation is that applicants must currently hold a Drug Establishment License (DEL) under Section C.01A.008 of the Food and Drug Regulations, which is required for the manufacturing of pharmaceuticals in general.*Full license requirements have not yet been published, but they are expected to resemble those of a Dealer’s License under the Narcotic Control Regulations.
Stay updated on U.S. cannabis legislation in Florida, Nebraska, and North Dakota. Learn how these changes affect cannabis businesses and compliance.
Initial Memo Restricts Sampling to Retail Stores On October 18, Alberta Gaming, Liquor and Cannabis (AGLC) issued a memo to cannabis businesses stating that cannabis
Court Rules Delta-8 THC from Legal Hemp is Not a Controlled Substance A U.S. Court of Appeals for the Ninth Circuit has ruled that Delta-8
This fall, Health Canada is anticipating sharing a policy consultation document about health products containing (CBD). Get a head start with detailed insights into these regulatory changes.
Subscribe To Our Newsletter
Get Latest Industry News and Updates